Based on the key indicators related to Tonix Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Tonix Pharmaceuticals Holding is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Tonix Pharmaceuticals' Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 11/23/2024, Other Stockholder Equity is likely to grow to about 741.7 M, though Retained Earnings are likely to grow to (570.6 M). Key indicators impacting Tonix Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Tonix Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Tonix Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tonix Pharmaceuticals.
Net Income
(110.83 Million)
Tonix
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Financing Activities
Sale Purchase Of Stock
Net Borrowings
Stock Based Compensation
Total Cashflows From Investing Activities
Depreciation
Other Non Cash Items
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Exchange Rate Changes
Investments
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Cash
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Total Current Assets
Common Stock
Accounts Payable
Short Long Term Debt Total
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Long Term Debt
Retained Earnings Total Equity
Non Current Liabilities Total
Capital Surpluse
Inventory
Other Current Assets
Deferred Long Term Liab
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Short Term Debt
Property Plant Equipment
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Non Current Liabilities Other
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Tax Expense
Depreciation And Amortization
Net Income From Continuing Ops
Research Development
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Non Operating Income Net Other
Interest Income
Net Interest Income
Reconciled Depreciation
Preferred Stock And Other Adjustments
Probability Of Bankruptcy
Understanding current and past Tonix Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tonix Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Tonix Pharmaceuticals' assets may result in an increase in income on the income statement.
Tonix Pharmaceuticals competes with Sonnet Biotherapeutics, Palisade Bio, Ibio, Jaguar Animal, and Vaxart. Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. The company was founded in 2007 and is headquartered in Chatham, New Jersey. Tonix Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Tonix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Tonix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tonix Pharmaceuticals competition to find correlations between indicators driving Tonix Pharmaceuticals's intrinsic value. More Info.
Tonix Pharmaceuticals Holding is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Tonix Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tonix Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Tonix Pharmaceuticals Systematic Risk
Tonix Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tonix Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Tonix Pharmaceuticals correlated with the market. If Beta is less than 0 Tonix Pharmaceuticals generally moves in the opposite direction as compared to the market. If Tonix Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tonix Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tonix Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Tonix Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Tonix Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tonix Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tonix Pharmaceuticals growth as a starting point in their analysis.
Tonix Pharmaceuticals November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tonix Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tonix Pharmaceuticals Holding. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tonix Pharmaceuticals Holding based on widely used predictive technical indicators. In general, we focus on analyzing Tonix Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tonix Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.